Dual-Action Oral Vaccine Platform

Engineered Probiotics Synthesizing Nanocyclobodies and Membrane-Displayed Antigens

Activating Immunity, Strengthening Defense

The predominant strategy to control these diseases relies on inactivated or attenuated vaccines tailored to each pathogen.

However, these vaccines have significant limitations: they require cold-chain storage, multiple doses, and individual administration.

Moreover, their effectiveness is often compromised by the rapid antigenic drift of viruses, enabling the emergence of new variants capable of evading immunity.

This creates a vicious cycle of slow vaccine development and delayed responses to emerging epidemics.

In this context, there is an urgent need for modular, scalable, and accessible vaccine platforms—solutions that can rapidly adapt to different viruses, be distributed without relying on complex infrastructure, and be applied on a large scale without specialized personnel.

Our Solution: AvianGuard

AvianGuard emerges as a response to this challenge: a dual-action oral probiotic vaccine platform, modular and low-cost, capable of adapting to different avian viruses through the redesign of its genetic components.

While the H5N1 case study validates its immediate applicability, its true potential lies in becoming a universal tool to mitigate multiple viral diseases in birds, preventing future crises through a preventive, accessible, and scalable approach.